GSE126463 pomalidomide MM1.S 0 v 3 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE126463_pomalidomide_MM1.S_0_v_3_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE126463_pomalidomide_MM1.S_0_v_3_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE126463_pomalidomide_MM1.S_0_v_3_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE126463_pomalidomide_MM1.S_0_v_3_human_up.

Results found

Linked to

 

Label

Description

 

Gene

Pvt1 oncogene

Gene

ZNFX1 antisense RNA 1

Gene

general transcription factor IIi pseudogene 4

Gene

CASTOR family member 3, pseudogene

Gene

pleckstrin homology and RUN domain containing M1 pseudogene 1

Gene

myocardial infarction associated transcript

Gene

general transcription factor IIi pseudogene 1

Gene

SH3BP5 antisense RNA 1

Gene

PCED1B antisense RNA 1

Gene

ASB16 antisense RNA 1


  • Gene

    ZNFX1 antisense RNA 1


  • Gene

    general transcription factor IIi pseudogene 4


  • Gene

    CASTOR family member 3, pseudogene


  • Gene

    pleckstrin homology and RUN domain containing M1 pseudogene 1


  • Gene

    myocardial infarction associated transcript


  • Gene

    general transcription factor IIi pseudogene 1


  • Gene

    SH3BP5 antisense RNA 1


  • Gene

    PCED1B antisense RNA 1


  • Gene

    ASB16 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.